Detalles de la búsqueda
1.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35322232
2.
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
N Engl J Med
; 384(9): 829-841, 2021 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33657295
3.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36919706
4.
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Lancet
; 398(10294): 27-40, 2021 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34102137
5.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24933332
6.
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
J Clin Oncol
; 42(17): 2012-2020, 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38382001
7.
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.
J Clin Oncol
; 41(1): 65-74, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35858154
8.
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
J Clin Oncol
; 41(35): 5388-5399, 2023 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37713657
9.
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
JCO Glob Oncol
; 8: e2100276, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35324270
10.
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
Clin Lung Cancer
; 21(5): e380-e387, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32213298
11.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer
; 19(3): 270-279.e3, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373274
12.
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
J Thorac Oncol
; 12(2): 383-389, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27464970
13.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer
; 112: 126-133, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191585
14.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Lung Cancer
; 93: 95-103, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898621
Resultados
1 -
14
de 14
1
Próxima >
>>